)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Orchid Pharma
Orchid Pharma (ORCHPHARMA) investor relations material
Orchid Pharma Q1 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 26/27 earnings summary21 Aug, 2026
Executive summary
Q1 FY 2027 revenue grew 15%-16% year-over-year to INR 304 crore, with gross margin improving to 33% from 30% in Q1 FY 2026.
EBITDA rose to INR 25 crore from INR 10 crore year-over-year, reflecting operational improvements and early merger synergies.
The merger with Dhanuka Laboratories became effective July 2026, creating an integrated anti-infective platform with expanded API and formulation capabilities.
Unaudited standalone and consolidated financial results for Q1 FY 2027 reflect the impact of the amalgamation and recent international acquisitions.
Positioned as a global leader in cephalosporin antibiotics, with India's only USFDA sterile cephalosporin approval and a differentiated value chain.
Financial highlights
Q1 FY27 standalone revenue from operations was ₹30,417.13 lakhs (INR 304 crore), up from ₹26,318.58 lakhs year-over-year.
Q1 FY27 standalone net profit was ₹1,193.72 lakhs, compared to a loss of ₹240.54 lakhs in Q1 FY26; consolidated net profit was ₹322.44 lakhs, up from a loss of ₹66.13 lakhs.
FY26 revenue was INR 1,233 crore, down from INR 1,398 crore in FY25 due to 15%-20% declines in key products and markets.
Standalone EBITDA for Q1 FY27 increased 178% year-over-year to ₹25 Cr, with EBITDA margin rising to 8% from 3% in Q1 FY26.
FY26 standalone PAT was ₹35 Cr versus ₹132 Cr in FY25; EBITDA margin dropped to 8% from 13%.
Outlook and guidance
Management expects initial benefits from merger integration projects to become visible in the next financial year.
Demand in regulated markets is cyclical, with H2 typically stronger; management anticipates better sales in upcoming quarters but refrained from providing specific annual growth guidance.
7-ACA facility expected to reach 80%-100% utilization by end of first year post-commissioning, with initial output used in-house.
FY25 and FY26 results revised to reflect the amalgamation from April 1, 2024, aligning financials with the new integrated structure.
The company continues to monitor regulatory changes, especially regarding new Labour Codes, and will adjust provisions as needed.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Orchid Pharma
- Profits and margins fell, but acquisitions and integration set up 10–15% growth for FY27.ORCHPHARMA
Q4 25/26 - Sales and margins fell, but profitability returned at PBT/PAT despite exceptional costs.ORCHPHARMAQ3 25/26
- Q2 FY26 saw sales and margins fall, but global acquisitions support future recovery.ORCHPHARMAQ2 25/26
- Q1 FY26 sales and profits dropped sharply, but margins and strategic initiatives were maintained.ORCHPHARMAQ1 25/26
- H1 FY25 sales up 22% YoY, net profit and margins improved, Orblicef launched in India.ORCHPHARMAQ2 24/25
- Q1 sales up 34%, EBITDA up 71%, profit up 169%, with strong CapEx and Cipla partnership.ORCHPHARMAQ1 24/25
- 9M FY25 revenue up 14–15%, PAT up 26%, with stable margins and ongoing project delays.ORCHPHARMAQ3 24/25
- Double-digit sales and profit growth achieved, but margin pressure and project delays persist.ORCHPHARMAQ4 24/25
Next Orchid Pharma earnings date
Q2 26/2710 Nov, 2026
Orchid Pharma
Next Orchid Pharma earnings date
Q2 26/2710 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Orchid Pharma Limited is a pharmaceutical company engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs) and finished dosage formulations. The company focuses on therapeutic areas such as anti-infectives, including beta-lactam antibiotics, and also operates in segments like cardiovascular and central nervous system treatments. Its operations include research and development, chemical synthesis, and formulation development for both domestic and international markets. The company is headquartered in Chennai, India, and its shares are listed on the BSE.